ACROBiosystems社 *Newly Launched Product* Full-length SMO Protein
Hedgehog (HH) signaling pathway is a conserved pathway involved in cell growth and tissue patterning. Its abnormal signal can be found in the skin, brain, liver, prostate, breast, and other cancers and hematologic malignancies, and participate in the regulation of cell growth, migration, and invasion.
Smoothened (SMO) is a promising target for suppressing HH signaling in treating a range of malignancies, with deep pocket structures that bind effectively and selectively to drugs. SMO inhibitors can inhibit cancer formation, reduce cancer cell proliferation, trigger apoptosis, and inhibit the activity of cancer stem cells. In addition, SMO inhibitors are another strategy to combat cancer stem cells. A better understanding of the HH/SMO pathway could lead to the developing of a new class of drugs with clinical efficacy.
SMO is a member of the G protein-coupled receptor (GPCR) family and a seven-pass transmembrane protein with the N-terminal extracellular and the C-terminal intracellular. ACROBiosystems has successfully developed HEK293 expressed full-length SMO-VLP protein (Arg28-Phe787) via "FLAG" to support drugs and therapies R&D targeting SMO.
The Structure of SMO
Full-length SMO-VLP Protein (Cat. No. SMO-H52P3)
★ High identity verified by DLS
The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
★ High bioactivity verified by ELISA
Immobilized Human SMO Full Length Protein-VLP (Cat. No. SMO-H52P3) at 10 μg/mL (100 μL/well) can bind Anti-SMO antibody with a linear range of 0.01-2.5 μg/mL (QC tested).
full-length multi-pass transmembrane proteins and technology platforms
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。